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Retinal pigment epithelium (RPE) is a valuable cell type for a number of blinding disorders. In this issue of
Cell Stem Cell, Idelson et al. (2009) use Nicotinamide and Activin A to markedly improve RPE yield from
human embryonic stem cells.Damage and dysfunction of the retinal
pigment epithelium (RPE), a monolayer of
black pigmented cells at the back of the
eye, play a critical role in the development
of diseases such as age-related macular
degeneration (AMD), affecting millions
worldwide, and retinitis pigmentosa (RP),
an inherited retinal degeneration. RPE is
an essential supporting layer for neural
retina, performing functions such as
phagocytosing and renewing the photore-
ceptor outer segments that house the
visual pigment, rhodopsin. Treatment for
these retinal disorders could include
replacement of damaged RPE and retinal
cells. Several potential cell sources have
been investigated: whole sheets of fetal
or adult RPE, and retina and dissociated
retinal cells have been used in transplant
experiments, but the limited amount of
donor tissue and poor cell integration
makes this treatment very inefficient, pre-
venting full visual recovery (for review see
da Cruz et al., 2007). New hope for retinal
cell replacement therapy comes from
human embryonic stem cells (hESCs),
offering an essentially unlimited source of
specific RPE and retina donor cells.
There has been considerable basic
research and private sector interest in
producing RPE cells for transplantation.
Protocols often rely on spontaneous gen-
eration of RPE, as highly confluent hESCs
or floating embryoid bodies (EBs) can
produce pigmented areas by 6–8 weeks,
albeit at very low incidence (Figure 1B)
(Klimanskaya et al., 2004; Lund et al.,
2006; Vugler et al., 2008). Excised pig-
mented areas grow into patches of cells
with typical RPE cobblestonemorphology
and express RPE markers such as
RPE65, CRALBP, and Bestrophin. Fur-
thermore, the cells become polarized
and phagocytose photoreceptor outer
segments in vitro and following transplan-
tation into the dystrophic retina of RoyalCollege of Surgeon (RCS) rats, which
have impaired phagocytosis due to a mu-
tation in the Mer receptor tyrosine kinase
gene. Thus, functional RPE cells have
been generated from hESCs via sponta-
neous differentiation, but the efficiency is
low and timing slow.
Understanding the normal process of
retinal cell specification (Figure 1A) can
help provide a logical framework for the
sequence of factors added to hESC cul-
tures to enrich for RPE cells. To date,
studies have focused on targeting the
early neural/non-neural decision. For in-
stance, a combination of the antagonists
Dkk1+Lefty or small molecule inhibitors
of Wnt and Nodal/Activin (Osakada et al.,
2009), and other combinations of early
pro-neural factors, such as noggin (a
BMP inhibitor), DKK1, and IGF1 (Lamba
et al., 2006), have been found to enhance
retina/RPE generation from human plurip-
otent sources.
Idelson et al. found serendipitously
(personal communication) that application
of nicotinamide (vitamin B3; NIC) to float-
ing EBs at this early commitment point
increased the number of developing pig-
mented areas dramatically, from 13% to
73% after 8 weeks. A group of transcrip-
tion factors required for eye-field specifi-
cation, including RX1, PAX6, SIX3, and
CHX10 (Zuber et al., 2003), was found to
be highly expressed in the NIC-treated
cultures. Some cells within the pigmented
areas also expressed MITF, a RPE tran-
scription factor, and RPE65, a mature
RPE marker. How does NIC act to stimu-
late RPE differentiation? Consistent with
its pleiotropic functions as a NAD-depen-
dent histone deacetylase inhibitor, the
authors find, using microarray profiling,
that both anterior neural genes and retinal
differentiation genes are upregulated in
NIC-treated cells. In addition, the authors
find that apoptosis is reduced and specu-Cell Stem Celllate that NIC, by inhibiting PARP, an
enzyme involved in DNA repair and
apoptosis, increases survival of the pre-
sumptive anterior neural plate cells.
The signaling pathways involved in eye
field specification from the anterior neural
plate have not yet been elucidated (for
review see Zaghloul et al., 2005). At the
later optic vesicle stage, Activin A pro-
duced from the extraocular mesenchyme
is known to promote RPE development,
while FGF directs the differentiation
toward neural retina rather than RPE
(Figure 1A). Thus, after 2 weeks of treat-
ment with NIC, Activin A was added and
found to increase the percentage of EBs
with pigmented areas (Figure 1B) and to
augment expression of MITF and Bestro-
phin. Substituting Activin A with bFGF,
however, prevented the differentiation of
hESCs toward pigmented cells. A better
yield of pigmented cells (33% after 6
weeks) was obtained when EBs grown in
NIC were dissociated and plated as a
monolayer with Activin A supplementa-
tion. The resulting pigmented cells had
typical RPE polygonal shape, tight junc-
tions, and marker expression and could
phagocytose photoreceptor outer seg-
ments.
To characterize functionality in vivo, the
authors transplanted RPE cells generated
fromaconstitutiveGFP+hESC line into the
subretinal space of RCS rats. Five weeks
post-transplantation, pigmented GFP+
RPE65+ Bestrophin+ cells were seen, oc-
casionally integrated within the host RPE,
but typically in a multilayered mass that
also contained nonpigmented cells. Nota-
ble thickening of the photoreceptor-
containing outer nuclear layer and preser-
vation of photoreceptor outer segments
was observed near the graft. Moreover,
rhodopsin was found in the pigmented
donor cells, suggesting the hESC-derived
RPE could phagocytose in vivo.5, October 2, 2009 ª2009 Elsevier Inc. 347
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Figure 1. Nicotinamide and Activin A Enhance RPE Differentiation from hESCs
(A) RPE embryogenesis. Retinal precursors originate in the eye field in themedial anterior neural plate. The
eye field splits, the neural plate rolls into the neural tube, and the eye-field derivatives evaginate bilaterally
from the diencephalon, creating two optic vesicles. The vesicles develop into two-layered optic cups, the
inner layer forming the neural retina and the outer layer the RPE.
(B) Summary of experimental protocols tested. hESCs were differentiated in serum-free media containing
Nicotinamide and Activin A. For suspension cultures, the number of EB/clusters that contained pigmented
areas were scored (percent of pigmented areas). The EBs were then dissociated and plated for 2 hours,
and the number of cells with pigment were counted (percent of pigmented cells). Figure drawn by Tim
Blenkinsop.Significantly improved electroretino-
graphic (ERG) response to light was
observed at 13 weeks post-transplanta-
tion; however, at 19 weeks, full-field ERG
responses became undetectable. At that
time point, the hESC-derived RPE cells
were still present, suggesting that the
partial visual rescueobtainedwasnot sus-
tained. Importantly, tumormasses or tera-
tomas were not detected up to 19 weeks
post-transplant.
Idelson et al. make important progress
toward using hESCs in the quest for RPE
replacement. Their finding that NIC en-
ables Activin A enhancement of RPE ge-
neration should encourage further studies
ofmolecules involved in RPE specification
decisions, in the future including the
elusive factors that stimulate eye-field
formation. This work also highlights sev-
eral significant hurdles. The resulting RPE
is still far from 100% pure, a challenge
when working with pluripotent cells that348 Cell Stem Cell 5, October 2, 2009 ª200must be approached to minimize the
possibility of tumor growth after long-
term transplantation. Additionally, charac-
terization with more than the few avail-
able markers is necessary to standardize
donor cells for transplantation. Why do
the surviving transplanted RPE cells lose
ERG function by 19 weeks? Does this
reflect the severity of themodel, instability
of phenotype, or poor integration? RPE
functions as a polarized monolayer bet-
ween the neural retina and the choroid
and a multilayered graft is, therefore, not
optimal. Cell suspensions are certainly
easier to transplant, especially into the
small eyes of murine models. In other cir-
cumstances, retinal surgeons can, how-
ever, perform remarkable feats, such as
rolling up RPE growing on a membrane,
sliding it under the retina, and then allow-
ing it to spontaneously unfold (Del Priore
et al., 2001), and organized, correctly
orientated RPEmay improve graft viability9 Elsevier Inc.(da Cruz et al., 2007). Finally, how the
immune system will respond to hESC-
RPE cells, especially in the diseased eye
where neovascularization with leaky
vessels is quite common, remains to be
determined.
The retina is a perfect place to make
headway in CNS stem cell transplanta-
tion—one can watch the implanted cells
to monitor growth and even laser rogue
cells that might overproliferate. Vision
loss is a severe burden, and while the
challenges are many, to quote Helen
Keller, ‘‘we can do anything we want to
do if we stick to it long enough.’’
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